129 Global differences in SAB management 6 15. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394–434. 16. Buis DTP, Sieswerda E, Kouijzer IJE, et al. [18f]FDG-PET/CT in Staphylococcus aureus bacteremia: a systematic review. BMC Infect Dis 2022; 22:282. 17. Duval X, Le Moing V, Tubiana S, et al. Impact of systematic whole-body 18F-fluorodeoxyglucose PET/CT on the management of patients suspected of infective endocarditis: the prospective multicenter TEPvENDO Study. Clin Infect Dis 2021; 73:393– 403. 18. van der Vaart TW, Prins JM, van Werkhoven CH, et al. Positive impact of [18F] FDG-PET/CT on mortality in patients with Staphylococcus aureus bacteremia explained by immortal time bias. Clin Infect Dis 2023:ciad112. 19. Thottacherry E, Cortés-Penfield NW. Evidence of clinical impact supports a new petition for medicare coverage of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/ computed tomography in the evaluation of Staphylococcus aureus bacteremia: a focused literature review and call to action. Clin Infect Dis 2022; 75:1457–61. 20. Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis 2020; 70:566–73. 21. Minejima E, Bensman J, She RC, et al. A dysregulated balance of proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia. Critic Care Med 2016; 44:671–9. 22. Kuehl R, Morata L, Boeing C, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis 2020; 20:1409–17. 23. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355:2395–407. 24. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341:1413–9. 25. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/ American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022; 79:e21–e129. 26. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018; 137:e67–e492. 27. Bai AD, Lo CKL, Komorowski AS, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28: 1076–84. 28. Warreman EB, Lambregts MMC, Wouters RHP, et al. Determinants of in- hospital antibiotic prescription behaviour: a systematic review and formation of a comprehensive framework. Clin Microbiol Infect 2019; 25:538–45. 29. Hagel S, Bahrs C, Schumann R, Pletz M, Weis S. Complicated and uncomplicated S. aureus bacteraemia: an international Delphi survey among infectious diseases experts on definitions and treatment. Clin Microbiol Infect 2022; 28:1026.e7–.e11. 30. Liu C, Strnad L, Beekmann SE, Polgreen PM, Chambers HF. Clinical practice variation among adult infectious disease physicians in the management of Staphylococcus aureus bacteremia. Clin Infect Dis 2019; 69:530–3.
RkJQdWJsaXNoZXIy MTk4NDMw